ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

• LEIDOS BIOMEDICAL RESEARCH INC

  UEI HV8BH9BPG8Y9

  $113.9M

  Subcontractor to this prime · 2 sub-awards · latest Nov 1, 2024

  • National Institutes of Health
  • “SUBCONTRACTOR SHALL CONTINUE TO ADDRESS UNMET NEEDS IN SARS-COV-2 SEROLOGICAL TESTING AND RESEARCH THROUGH INVESTIGATION OF CHARACTERISTICS OF THE IMMUNE RESPONSE THAT CORRELATE WITH PROTECTION FROM INFECTION OR SEVERE DISEASE, WITH A FOCUS ON CANCER PATIENTS. LONGITUDINAL STUDIES SHALL CONTINUE ONLY IN THE MULTIPLE MYELOMA COHORT; IN HEMATOLOGICAL CANCER TRANSPLANT RECIPIENTS (WITH AND WITHOUT HIV)AND WITH HEALTHY CONTROLS TO ACHIEVE MATCHED TIME POINTS. THIS WORK WILL BE CONDUCTED IN PARTNERSHIP WITH SERONET; INCLUDING THE FNLCR SEROLOGY LABORATORY; AND THE SSC; TO DEVELOP AND PROVIDE REAGENTS AND STANDARDS TO THE SEROLOGY COMMUNITY ONCE GENERATED AND QUALIFIED. TECHNOLOGY DEVELOPMENT INCLUDES CONDUCTING A PILOT TO ADDRESS THE POSSIBILITY OF INCREASED INCIDENCE OF CANCER DUE TO SARS-COV-2 AS WELL AS COLLECTIONS FROM NOVEL VACCINE RECIPIENTS.”
  • “THE OBJECTIVE OF THE FOLLOWING PUBLIC HEALTH INVESTIGATIONS IS TO DETERMINE THE ANTI-SARS-COV-2 ANTIBODY LEVELS AND SARS-COV-2 TOTAL NEUTRALIZING ANTIBODY PREVIOUSLY EXPOSED TO SARS-COV-2 AND/OR VACCINATED WITH CURRENT COVID-19 VACCINES, USING VALIDATED SARS-COV-2 SEROLOGICAL ASSAYS WITH EVIDENCE OF HIGH SPECIFICITY AND SENSITIVITY. STUDY 1: IN THE NCI COVID-19 IN CANCER PATIENTS STUDY (NCCAPS) PATIENTS, THE PLAN IS TO INVESTIGATE LONGITUDINAL ANTIBODY RESPONSE TO SARS-COV-2 INFECTION AND VACCINATION. STUDY 2: IN THE NCI CLINICAL CENTER STUDY, THE OBJECTIVE IS TO INVESTIGATE THE SAFETY AND IMMUNOGENICITY OF THE COVID-19 VACCINE (MRNA-1273) IN PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES AND VARIOUS REGIMENS OF IMMUNOSUPPRESSION AND IN PARTICIPANTS WITH SOLID TUMORS ON PD1/PDL1 INHIBITOR THERAPY, INCLUDING BOOSTER DOSES OF VACCINE. STUDY 3: IN THE CHILDREN'S ONCOLOGY GROUP (COG) STUDY, THE OBJECTIVE IS TO EVALUATE IMMUNOLOGIC RESPONSE FOLLOWING COVID-19 VACCINATION IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH CANCER.”
• UNIVERSITY OF MONTANA

  UEI DAY7Z8ZD48Q3 · not in the directory yet

  $575K

  Subcontractor to this prime · 1 sub-award · latest Feb 6, 2025

  • National Institutes of Health
  • “DEVELOP AND ADVANCE A DURABLE CROSS-PROTECTIVE ADJUVANTED H5N1 AND H5N2 SUBUNIT VACCINES.”
• NORTHEASTERN UNIVERSITY

  UEI HLTMVS2JZBS6

  $49.7K

  Subcontractor to this prime · 1 sub-award · latest Jul 22, 2026

  • National Aeronautics and Space Administration
  • “FOR THIS PROJECT, SUBRECIPIENT'S TEAM WILL PROVIDE HUMAN ES CELLS CARRYING THE H2BGFP REPORTER. THEY WILL ALSO GENERATE MICROGLIA AND OTHER CELL TYPES THAT WILL BE DERIVED FROM HUMAN ES CELLS. IN ADDITION, THEY WILL HELP WITH THE EXPERIMENTAL DESIGN AND INTERPRETATION OF DATA RELATED TO INFLAMMATION-MEDIATED NEURODEGENERATION.”

• VIVALDI BIOSCIENCES INC.

  UEI M3MMUF255NY1 · not in the directory yet

  $2M

  Subcontracted by this company · 1 sub-award · latest Nov 16, 2023

  • National Institutes of Health
  • “OPTION 11A (0258-A468-4609) GENERATION OF GMP REAGENT DELTAFLU H5/1 THE PURPOSE OF THIS OPTION IS TO GENERATE A NEEDED REAGENT TO CONDUCT A UNIVERSAL INFLUENZA VIRUS VACCINE CLINICAL TRIAL SPONSORED BY THE CIVIC PROGRAM. THE SPECIFIC REAGENT CONSISTS OF A GMP MANUFACTURED FINAL DRUG PRODUCT (FDP) AND THE ASSOCIATED QC INFORMATION OF THE LIVE ATTENUATED VIRUS VACCINE DELTAFLUH5/1. THIS LIVE ATTENUATED VIRUS VACCINE CONSISTS OF AN INFLUENZA A VIRUS DELETED FOR THE NS1 GENE AND CONTAINING A CHIMERIC HEMAGGLUTININ (HA) WITH THE HEAD OF AN H5 VIRUS AND THE STALK OF AN H1 VIRUS. THIS REAGENT WILL BE USED IN A CIVIC SPONSORED CLINICAL TRIAL TOGETHER WITH A GMP MANUFACTURED FDP OF THE LIVE ATTENUATED VIRUS VACCINE DELTAFLUH12/1 VIRUS, THAT WILL BE GENERATED UNDER AN ADDITIONAL OPTION 11. THE FOLLOWING SPECIFIC AIMS ARE PROPOSED: AIM 1: PERFORM GMP PRODUCTION AND FILLING OF THE DELTAFLUH5/1 FDP FROM A BULK DRUG SUBSTANCE (BDS) STARTING MATERIAL GENERATED UNDER GRANT R01AI141226. AIM 2: PERFORM QC TESTS OF THE DELTAFLUH5/1 FDP. OPTION 11B (0258-A469-4609) GENERATION OF GMP REAGENT DELTAFLU H12/1 THE PURPOSE OF THIS OPTION IS TO GENERATE A NEEDED REAGENT TO CONDUCT A UNIVERSAL INFLUENZA VIRUS VACCINE CLINICAL TRIAL SPONSORED BY THE CIVIC PROGRAM. THE SPECIFIC REAGENT CONSISTS OF A GMP MANUFACTURED FINAL DRUG PRODUCT (FDP) AND THE ASSOCIATED QC INFORMATION OF THE LIVE ATTENUATED VIRUS VACCINE DELTAFLUH12/1. THIS LIVE ATTENUATED VIRUS VACCINE CONSISTS OF AN INFLUENZA A VIRUS DELETED FOR THE NS1 GENE AND CONTAINING A CHIMERIC HEMAGGLUTININ (HA) WITH THE HEAD OF AN H12 VIRUS AND THE STALK OF AN H1 VIRUS. THIS REAGENT WILL BE USED IN A CIVIC SPONSORED CLINICAL TRIAL TOGETHER WITH A GMP MANUFACTURED FDP OF THE LIVE ATTENUATED VIRUS VACCINE DELTAFLUH5/1 VIRUS, THAT WILL BE GENERATED UNDER AN ADDITIONAL OPTION 11. THE FOLLOWING SPECIFIC AIMS ARE PROPOSED: AIM 1: PERFORM GMP PRODUCTION AND FILLING OF THE DELTAFLUH12/1 FDP FROM A BULK DRUG SUBSTANCE (BDS) STARTING MATERIAL”
• ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC)

  UEI QKXVTWJFQKA9 · not in the directory yet

  $1.5M

  Subcontracted by this company · 1 sub-award · latest Mar 18, 2024

  • National Institutes of Health
  • “OPTION 16D: 0258-A740-4612 IN THIS PROJECT, WE WILL STUDY NON-HOMOLOGOUS RECOMBINATION (NHR) IN THE CONTEXT OF THE ACQUISITION OF A MULTI-BASIC CLEAVAGE SITE IN THE HEMAGGLUTININ OF H7 AVIAN INFLUENZA VIRUSES. WE WILL INVESTIGATE THE POTENTIAL INVOLVEMENT OF SMALL NUCLEOLAR RNAS AND OTHER POTENTIAL VIRAL AND HOST FACTORS IN NHR USING VIRAL RIBONUCLEOPROTEINS RECONSTITUTIONS IN CELLS AND REPLICATION-DEFICIENT VIRUSES. OPTION 14A: IF300302084-940003 IN THIS PROJECT, WE WILL PERFORM A PRE-CLINICAL STUDY IN FERRETS TO ASSESS THE IMMUNOGENICITY AND PROTECTION OF H5 MRNA VACCINES. TWO ANTIGENS WILL BE COMPARED: OUR RECENTLY DESIGNED ANTIGENICALLY CENTRAL (AC) ANHUI ANTIGEN AND A/ASTRAKHAN/3212/2020, ANTIGEN FROM THE SEQIRIUS VACCINE. HOMOLOGOUS PRIME-BOOST AND HETEROLOGOUS PRIME-BOOST REGIMENS (AC-ANHUI PRIME AND ASTRAKHAN BOOST AND VICE-VERSA) WILL BE COMPARED. H5 SPECIFIC T-CELL WILL BE MEASURED AND ANTIBODY LANSDCAPES SHOWING THE BREADTH OF SERA REACTIVITY AGAINST OVER 100 H5 ANTIGENS WILL BE BUILT. FERRETS WILL BE CHALLENGED WITH HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUS FROM THE ONGOING US CATTLE OUTBREAK. OPTION 12C: IF300302132-940003 THE OVERALL OBJECTIVE OF THIS PROJECT IS TO PERFORM A BROAD AND IN-DEPTH CHARACTERIZATION OF INFLUENZA VIRUS-SPECIFIC IMMUNE RESPONSES USING DOWNSTREAM SEROLOGICAL, B- AND T-CELL ANALYSES OF SAMPLES COLLECTED PRE- AND POST-VACCINATION DURING AN NIH SPONSORED CLINICAL TRIAL ASSESSING A ANTIGENICALLY CENTRAL H5 VACCINE IN HUMANS.”
• UNIVERSITY OF MARYLAND, BALTIMORE

  UEI Z9CRZKD42ZT1 · not in the directory yet

  $1.2M

  Subcontracted by this company · 2 sub-awards · latest May 22, 2024

  • National Institutes of Health
  • “OPTION 12B: DESCRIPTION OF WORK: IN SUPPORT OF THE MUCOSAL SAMPLING CONSORTIUM TO INFORM PROJECT NEXTGEN, THE CENTER FOR VACCINE DEVELOPMENT AND GLOBAL HEALTH (CVDGH) AT UMB WILL COLLECT MUCOSAL AND BLOOD SAMPLES THROUGH AN EXISTING DONOR PROTOCOL (CVD 4000). SAMPLES WILL EITHER BE SHIPPED DIRECTLY TO A CENTRAL REPOSITORY OR WILL BE PROCESSED AT UMB AND THEN SHIPPED TO THE REPOSITORY. NASAL AND SALIVA SAMPLES FROM ALL FOUR CONSORTIUM SITES WILL BE SHIPPED FROM THE CENTRAL REPOSITORY TO DR. MARCELA PASETTI€„¢S APPLIED IMMUNOLOGY LABORATORY (AIL) FOR MUCOSAL ANTIBODY ANALYSES. A. CVDGH CLINIC: THE CLINIC WILL BE RESPONSIBLE FOR CONSENTING AND ENROLLING ELIGIBLE DONORS IN THE BLOOD DONOR CVD 4000 PROTOCOL. AFTER ENROLLMENT AND SCREENING, MUCOSAL AND BLOOD SAMPLES (TABLE 1) WILL BE COLLECTED FROM 10-15 PARTICIPANTS ON DAY 1, DAY 3, AND DAY 15 USING HARMONIZED SAMPLING PROTOCOLS. THE CLINIC WILL COLLECT AND SECURELY MAINTAIN DEMOGRAPHIC AND BASELINE MEDICAL DATA. I. UP TO 270 SAMPLES WILL BE COLLECTED. TWO NASAL AND TWO SALIVA SAMPLES WILL BE COLLECTED AT EACH VISIT FROM EACH PARTICIPANT (LEFT AND RIGHT SIDES). ONE MID-TURBINATE SWAB WILL BE COLLECTED FROM EACH PARTICIPANT AT ALL TIMEPOINTS. AT ONE TIMEPOINT, VENOUS BLOOD WILL BE COLLECTED FROM PARTICIPANTS FOR PBMCS, SERUM, AND/OR PLASMA. B. APPLIED IMMUNOLOGY LABORATORY: THE AIL (PASETTI LAB) SPECIMEN PROCESSING GROUP WILL BE RESPONSIBLE FOR PROCESSING (PBMCS, SERUM, PLASMA), LABELING, STORING, AND SHIPPING ALL SAMPLES COLLECTED BY THE CLINIC. ADDITIONALLY, THE AIL WILL CONDUCT ANALYSES ON NASAL AND SALIVARY SAMPLES TO QUANTIFY BINDING ANTIBODIES SPECIFIC TO SARS-COV-2 ANTIGENS AND TOTAL ANTIBODIES. I. SPECIMEN PROCESSING AND MANAGEMENT: THE AIL SPECIMEN PROCESSING GROUP WILL RECEIVE THE OUTLINED SAMPLES (TABLE 1) FROM THE CVDGH CLINIC. NASAL SECRETIONS (NASOSORPTION), SALIVA (ORACOL+), AND NASAL CELL (MID-TURBINATE SWAB) SAMPLES WILL BE LABELED, DOCUMENTED, RECORDED IN GLOBALTRACE, AND STORED PER THE P”
  • “UMB WILL BE RESPONSIBLE FOR THE DESIGN, IMPLEMENTATION, ANALYSIS AND RESULTS DISSEMINATION OF THE PHASE 1 CLINICAL TRIAL OF A SARS-COV-2 MULTIVALENT VACCINE. THIS WILL INCLUDE THE PERFORMANCE OF SPECIFIED IMMUNOLOGIC AND VIROLOGIC ASSAYS. AS SUCH, UMB WILL BE INVOLVED IN PRECLINICAL ACTIVITIES TO INFORM TRIAL DESIGN AND PREPARE FOR TRIAL IMPLEMENTATION, TO INCLUDE DRAFTING SOPS AND CRFS, COMPLETING REQUIRED REPORTS AND OBTAINING ALL NECESSARY REGULATORY AND ETHICS APPROVALS.”
• UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

  UEI D3LHU66KBLD5

  $1.2M

  Subcontracted by this company · 1 sub-award · latest Mar 22, 2024

  • National Institutes of Health
  • “OPTION 9B: 0258-A730-4609 RECOVERY AND IMMUNOLOGIC COMPARISONS ACROSS THE GROUP B MERBECOVIRUSES USING ANTIGENIC CARTOGRAPHY INTRODUCTION: MERBECOVIRUSES INCLUDE A DIVERSE ARRAY OF POSITIVE STRANDED RNA VIRUSES WITHIN THE BETACORONAVIRUS GENUS AND INCLUDE THE HIGHLY PATHOGENIC MERS-COV STRAIN THAT CAUSED 2604 LABORATORY-CONFIRMED CASES OF MIDDLE EAST RESPIRATORY SYNDROME (MERS) INCLUDING 936 ASSOCIATED DEATHS AT A CASE-FATALITY RATIO (CFR) OF 36% SINCE 2012. IMPORTANTLY, NUMEROUS ZOONOTIC BAT MERS-LIKE VIRUSES CIRCULATE IN NATURE INCLUDING SEVERAL STRAINS THAT CAN USE THE HUMAN DIPEPTIDYL PEPTIDASE RECEPTOR (HDPP4) FOR DOCKING AND ENTRY. SOME REPLICATE EFFICIENTLY OR ARE ANTICIPATED TO REPLICATE EFFICIENTLY IN PRIMARY HUMAN AIRWAY EPITHELIAL CELLS (E.G., MERS-422, MJHKU4R -COV-1, NEO, ), WHILE MOST HAVE NOT BEEN STUDIED. CURRENTLY, THERE ARE NO APPROVED VACCINES OR THERAPEUTICS FOR USE AGAINST MERS-COV INFECTION OR ANY OTHER MERBECOVIRUS. GIVEN THE EXTREME PATHOGENIC POTENTIAL OF MERS-COV, COUPLED WITH THE PRESENCE OF MERBECOVIRUSES THAT CAN USE DPP4 OR ANGIOTENSIN 1 CONVERTING ENZYME 2 (ACE2) AS RECEPTORS FOR DOCKING AND ENTRY, THE DEVELOPMENT OF PANMERBECOVIRUS VACCINES IS STILL CONSIDERED HIGH PRIORITY TARGETS FOR COUNTERMEASURE INVESTMENTS BY HEALTH AGENCIES ACROSS THE WORLD (HTTPS://WWW.WHO.INT/TEAMS/BLUEPRINT). THE OVERARCHING GOAL OF THIS PROPOSAL IS TO DETERMINE THE ANTIGENIC DISTANCE BETWEEN HIGHLY HETEROGENEOUS MERBECOVIRUSES, CREATE AN ANTIGENIC CARTOGRAPHY MAP, AND PRODUCE DEFINED SERA AND RECOMBINANT VIRUS REAGENTS THAT WILL ENHANCE GLOBAL PREPAREDNESS AGAINST FUTURE MERBECOVIRUS EPIDEMICS AND PANDEMICS. THE PROPOSAL HAS THREE AIMS: AIM I) PRODUCTION AND CHARACTERIZATION OF MERBECOVIRUS SPIKE ANTIGENS AND PRODUCTION OF MURINE ANTISERUM. FROM PUBLISHED SEQUENCES, MERBECOVRIRUS SPIKE GENES WILL BE SYNTHESIZED AND EXPRESSED AT UNC€„¢S PROTEOMIC CORE. RECOMBINANT PROTEINS PLUS ADJUVANT WILL BE INJECTED INTO RODENTS FOR THE PRODUCTION OF SERU”
• EMORY UNIVERSITY

  UEI S352L5PJLMP8

  $869.6K

  Subcontracted by this company · 1 sub-award · latest Mar 18, 2024

  • National Institutes of Health
  • “OPTION 2: 0258-C504-4609 OPTION 3: 0258-D504-4609 OPTION 4: IF300302118-940002 OPTION 5: IF300302188-940002 THE WORK PERFORMED BY DR. MEDINA AND HIS COLLABORATORS WILL INCLUDE: 1. SURVEILLANCE OF HUMAN INFLUENZA VIRUS IN THE METROPOLITAN AREA OF SANTIAGO. 2. ENROLMENT OF HUMAN SUBJECTS UNDER AN APPROVED IRB PROTOCOL ALLOWING THE COLLECTION OF INFLUENZA CLINICAL SAMPLES AND METADATA. 3. COLLECTION OF 250 INFLUENZA CLINICAL SAMPLES FOR VIRUS ISOLATION AND TO ANALYZE IMMUNE RESPONSES. 4. ESTABLISHING A CLINICAL SAMPLE DATABASE. 5. CHARACTERIZATION (SUBTYPING) OF VIRAL STRAINS AND HOST IMMUNE RESPONSES DURING ACUTE INFECTION FROM 250 VIRAL SAMPLES OBTAINED FROM INDIVIDUALS. 6. SUBMITTING BI-MONTHLY, SEMI-ANNUAL AND ANNUAL CLINICAL PROGRESS REPORTS. 7. SURVEILLANCE OF SWINE INFLUENZA VIRUSES IN THE CENTRAL REGIONS OF CHILE. 8. CHARACTERIZATION OF SWINE VIRAL STRAINS AND GENOTYPES. 9. PERFORMING ANTIGENIC CHARACTERIZATION OF SELECTED ANIMAL STRAINS. 10. COLLABORATING AND EXCHANGING RESEARCH MATERIALS WITH MEMBERS OF THE CENTER. 11. ATTENDING THE CEIRS NETWORK ANNUAL MEETING. 12. ATTENDING SCIENTIFIC ADVISORY BOARD MEETINGS AND CLINICAL SITE VISITS.”
• REGENTS OF THE UNIVERSITY OF MINNESOTA

  UEI KABJZBBJ4B54

  $800K

  Subcontracted by this company · 1 sub-award · latest Feb 25, 2025

  • National Institutes of Health
  • “OPTION 23C: 0258-A485-4609 OPTION 23D: 0258-A486-4609 THE UNIVERSAL INFLUENZA VACCINE TECHNOLOGY LANDSCAPE IS A UNIQUE, OPEN-ACCESS DATABASE OF INFORMATION ON UNIVERSAL, BROADLY PROTECTIVE, AND NEXT-GENERATION INFLUENZA VACCINES, AS DEFINED IN THE INFLUENZA VACCINES R&D ROADMAP, IN CLINICAL AND PRECLINICAL DEVELOPMENT. AS OF MAY 2024, THE LANDSCAPE PROFILED MORE THAN 200 VACCINE CANDIDATES IN THE R&D PIPELINE IN ACADEMIC, GOVERNMENT, AND INDUSTRY LABORATORIES, INCLUDING COVID-INFLUENZA COMBINATION VACCINES IN CLINICAL DEVELOPMENT, ACROSS SIX DIFFERENT VACCINE PLATFORMS. DATA ON EACH VACCINE CANDIDATE ARE SUMMARIZED BY PHASE, PLATFORM, TECHNICAL APPROACH, GOAL, AND STATUS OF DEVELOPMENT. THE LANDSCAPE IS ONLINE AND OPEN ACCESS, AND THE ENTIRE DATASET CAN BE DOWNLOADED AS A CSV FILE. A SMALL GROUP OF SUBJECT-MATTER EXPERTS IN INFLUENZA VACCINE R&D AND/OR VACCINE DATABASE DEVELOPMENT PROVIDES ADVICE ON THE DEVELOPMENT OF THE LANDSCAPE. THE OBJECTIVE OF THIS PROJECT IS TO CONTINUE DEVELOPING AND MAINTAINING INFORMATION ON THE LANDSCAPE TO INCLUDE AN UP-TO-DATE, COMPREHENSIVE, AND ACCURATE OVERVIEW OF VACCINE CANDIDATES IN PRECLINICAL DEVELOPMENT FOR UNIVERSAL, BROADLY PROTECTIVE, AND NEXT-GENERATION INFLUENZA VACCINES. SPECIFIC ACTIVITIES: 1. COLLECT AND CURATE INFORMATION ON UNIVERSAL, BROADLY PROTECTIVE, AND NEXT-GENERATION INFLUENZA VACCINES TECHNOLOGIES IN PRECLINICAL DEVELOPMENT FROM A WIDE RANGE OF PUBLICLY AVAILABLE SOURCES. CONTINUE RESEARCH ON UNIVERSAL, BROADLY PROTECTIVE, AND NEXT-GENERATION INFLUENZA VACCINE TECHNOLOGIES; MONITOR KEY SOURCES OF INFORMATION FROM THE SCIENTIFIC LITERATURE, PREPRINT SERVERS, AND INDUSTRY WEBSITES AND NEWS SOURCES; AND CROSSCHECK DATA ON VACCINE TECHNOLOGIES IN THE DATABASE. 2. UPLOAD NEW OR REVISED INFORMATION ON THE IVR LANDSCAPE WEBSITE ON A WEEKLY BASIS, FOR DISPLAY IN THE SNAPSHOT GRAPHIC AND DATABASE TABLE, AND MONITOR DATA FOR COMPLETENESS AND ACCURACY. 3. DISSEMINATE INFORMATION ON R&D OF INFLUENZA CANDIDAT”
• BIORELIANCE CORPORATION

  UEI H3KAG9A26K77

  $726.9K

  Subcontracted by this company · 1 sub-award · latest Jul 29, 2025

  • National Institutes of Health
  • “CONDUCT QUALITY CONTROL RELEASE TESTING ON SAMPLES OF TRADITIONAL VACCINES, SPECIFICALLY FOCUSING ON THE FOLLOWING PRODUCTS: NDV MASTER SEED, NDV FINAL PRODUCT, AND NDV BULK HARVEST. PLEASE REFER TO QUOTE NUMBERS R-10151426.1, R-10151430.1, AND R-10151438.1, ATTACHED AND INCORPORATED HEREIN, FOR DETAILED SPECIFICATIONS.”
• WASHINGTON UNIVERSITY, THE

  UEI L6NFUM28LQM5

  $492.1K

  Subcontracted by this company · 1 sub-award · latest May 22, 2024

  • National Institutes of Health
  • “OPTION 23B: 0258-A464-4609 WE FIRST OPTIMIZE THE MINIHA OVERALL CONSTRUCT AND IN PARALLEL DEVELOP CONSENSUS VARIANTS. IF BOTH SUCCESSFUL, IN A SECOND STEP, KNOWLEDGE FROM AIM 1 AND 2 WILL BE COMBINED TO DEVELOP A FOLDON INDEPENDENT CONSENSUS MINIHA FOR EACH GROUP 1, 2 AND IVB. AIM 1: DEVELOP HEADLESS MINI HA MOLECULES FOR H1 AND H3 HA WE WILL GENERATE TRIMERIC MINIHA. WE WILL FOCUS ON COMMONLY USED STRAINS (A/CA/04/09 PDMH1N1 (CAL/09) FOR GROUP 1, A/VICTORIA/361/11 H3N2 (VIC/11) FOR GROUP 2. WE ALSO INCLUDED H7. ONCE THESE VARIATIONS ARE ESTABLISHED AS STABLE, TRIMERIC PROTEINS, WE WILL APPROACH IVB STARTING WITH B/WA/02/19 B/VIC (B/WA/19). 1. OPTIMIZATION CUT SITE RECONNECTIONS. 2. OPTIMIZATION OF HELICAL INTERFACE CONTACTS. AIM 2: DEVELOP CONSENSUS HEADLESS MINI-HA TO TARGET INFLUENZA A AND B USING SEVERAL STRATEGIES TO CLUSTER INFLUENZA SEQUENCE ALIGNMENTS WE WILL GENERATE AS POSITION-SPECIFIC SCORING MATRIX (PSSM) TO GENERATE A CONSENSUS-BASED REDESIGN OF THE TEMPLATE STRUCTURE WHICH WILL BE TAKEN FROM VARIANTS OF AIM 1. TO AVOID BIAS CAUSED BY THE STARTING CRYSTAL STRUCTURE, WE WILL UTILIZE MULTIPLE TEMPLATES. CONSTRUCTS WILL BE EXPRESSED AND BIOCHEMICALLY EVALUATED. OPTION 12C: 0258-A483-4609 WE WILL ESTABLISH A METHOD FOR THE DETAILED EVALUATION OF NEUTRALIZATION POTENTIAL OR SERUM BINDING PROFILES. AIM 1: ASSAY OPTIMIZATION AND PROOF-OF-PRINCIPLE. WE WILL OPTIMIZE PSEUDOVIRUS TITERS AND IDENTIFY IDEAL EXPERIMENTAL CONDITIONS USING TWO HEMAGGLUTININ OF DIFFERENT INFLUENZA STRAINS AS PROTOTYPES. AIM 2: EVALUATION OF SENSITIVITY AND EVALUATION OF PREDEFINED ANTIBODY COMBINATIONS. WE WILL EXAMINE (1.) SURFACE DISPLAY OF HA AFTER PV INFECTION AND GENOME INTEGRATION TO STANDARDIZE THE BINDING ASSAY, (2) NEUTRALIZATION POTENTIAL AND SENSITIVITY USING 4 PREVIOUSLY CHARACTERIZED ANTIBODIES TO STEM, ANCHOR EPITOPE, RECEPTOR BINDING SITE AND LATERAL PATCH. AIM 3: LIBRARY GENERATION AND ESTABLISH POOL-BASED ANALYSIS. WE WILL GENERATE”
• UNIVERSITAET FUER BODENKULTUR WIEN

  UEI XJTMWC8W6EW7 · not in the directory yet

  $459.2K

  Subcontracted by this company · 1 sub-award · latest Jul 15, 2024

  • National Institutes of Health
  • “OPTION 11C: 0258-A474-4612 DEVELOPMENT OF A TAG-LESS RNA DOWNSTREAM PURIFICATION PROCESS AND ASSISTANCE IN OPTIMIZING AN AFFINITY-BASED RNA DOWNSTREAM PURIFICATION PROCESS THE UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES, VIENNA WILL AID IN THE BIOPROCESS DEVELOPMENT OF A NOVEL RECOMBINANT INFLUENZA VIRUS NEURAMINIDASE. THIS PROTEIN IS INTENDED TO BE USED AS A SUBUNIT VACCINE. RECOMBINANT NEURAMINIDASE (RNA) WILL BE PRODUCED IN INSECT CELLS, USING THE BACULOVIRUS SYSTEM, AT MOUNT SINAI AND/OR EXPRESSION SYSTEMS. DR. LINGG€„¢S TEAM WILL DEVELOP A DOWNSTREAM PROCESS (DSP) FOR HIGHLY PURE RNA USING TWO STRATEGIES. FIRSTLY, AN ALREADY EXISTING POLY-HISTIDINE-TAG BASED DSP WILL BE OPTIMIZED TO ENSURE A ROBUST PROCESS WITH A YIELD SUFFICIENT TO SUPPORT PHASE I CLINICAL TRIAL PRODUCTION AT EXPRESSION SYSTEMS. SECONDLY, A NOVEL DSP THAT DOES NOT RELY ON THE POLY-HISTIDINE-TAG, WILL BE DEVELOPED. TASK 1: OPTIMIZE AFFINITY-BASED PROCESS THE CURRENT AFFINITY-BASED PROCESS UTILIZES POLY-HISTIDINE TAGGED RNA WHICH CAN BE PURIFIED USING IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY. WHILE THE PROCESS PRODUCES RNA OF SUFFICIENT PURITY, IT SUFFERS FROM LOW SCALABILITY DUE TO LACKING ROBUSTNESS OF THE PROCESS. PROTEIN LOSSES DURING COLUMN WASH STEPS WERE OBSERVED. THE AFFINITY CHROMATOGRAPHY STEP WILL BE OPTIMIZED USING VARIOUS STRATEGIES AND AN ARRAY OF ANALYTICAL TOOLS TO MONITOR THE CONCENTRATION OF PRODUCT AND CRITICAL IMPURITIES. OPTION 11D: 0258-A475-4612 DEVELOPMENT OF A TAG-LESS RNA DOWNSTREAM PURIFICATION PROCESS AND ASSISTANCE IN OPTIMIZING AN AFFINITY-BASED RNA DOWNSTREAM PURIFICATION PROCESS THE UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES, VIENNA WILL AID IN THE BIOPROCESS DEVELOPMENT OF A NOVEL RECOMBINANT INFLUENZA VIRUS NEURAMINIDASE. THE WORK ON THIS OPTION WILL BE AS FOLLOWS: TASK 2: DEVELOP TAG-LESS PROCESS A CONVENTIONAL DSP FOR THE PRODUCTION OF RNA WITHOUT AFFINITY TAG WILL BE DEVELOPED USING STATE-OF-THE-ART BIOCHEMICAL”
• SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

  UEI KUKXRCZ6NZC2

  $151.4K

  Subcontracted by this company · 1 sub-award · latest Jul 16, 2026

  • National Institutes of Health
  • “IF300302118-940002 (OPTION 4) IF300302188-940002 (OPTION 5) MARTA LUKSZA, PH.D., AT MEMORIAL SLOAN KETTERING CANCER CENTER (MSKCC), WILL CONDUCT COMPUTATIONAL ANALYSES OF RESPIRATORY VIRUS EVOLUTION WITH A FOCUS ON INFLUENZA VIRUSES AND SARS-COV-2. THE PROJECT WILL PURSUE THREE DEFINED OBJECTIVES: (1) DEVELOP EFFICIENT ALGORITHMS AND PIPELINES FOR PHYLOGENY AND REASSORTMENT RECONSTRUCTION; (2) PERFORM COMPUTATIONAL FITNESS ANALYSIS OF CIRCULATING INFLUENZA STRAINS; AND (3) PROVIDE TOOLS FOR VISUALIZATION OF GLOBAL AND REGIONAL PHYLOGENIES OF RESPIRATORY VIRUSES. ACTIVITIES WILL INCLUDE LARGE-SCALE TIME-RESOLVED PHYLOGENETIC RECONSTRUCTION USING VIRAL SEQUENCE DATA FROM GISAID AND THE GOTHAM COHORT, DEVELOPMENT AND OPTIMIZATION OF MULTI-SEGMENT REASSORTMENT DETECTION METHODS, AND APPLICATION OF ESTABLISHED FITNESS MODELING FRAMEWORKS TO ASSESS THE EVOLUTIONARY TRAJECTORIES OF CIRCULATING STRAINS. THE PROJECT WILL ALSO MAINTAIN AND EXPAND WEB-BASED VISUALIZATION TOOLS TO DISSEMINATE PHYLOGENETIC, REASSORTMENT, AND FITNESS ANALYSES AND WILL SUPPORT COORDINATION WITH EXPERIMENTAL LABORATORIES THROUGH IDENTIFICATION AND SELECTION OF REPRESENTATIVE VIRAL ISOLATES FOR PHENOTYPIC FOLLOW-UP. ALL WORK WILL BE PERFORMED AT MSKCC USING EXISTING COMPUTATIONAL INFRASTRUCTURE AND CURATED VIRAL SURVEILLANCE DATASETS.”
• FUNDACION UNIVERSITARIA SAN PABLO-CEU

  UEI YJARMWMMEWW6 · not in the directory yet

  $119K

  Subcontracted by this company · 1 sub-award · latest Jul 23, 2025

  • National Institutes of Health
  • “OPTION 4: IF300302117-911011 OPTION 5: IF300302187-911011 SURVEILLANCE AND ANTIGENIC, PHENOTYPIC AND GENETIC CHARACTERIZATION OF SWINE INFLUENZA VIRUSES ISOLATED IN SPAIN THE OVERALL OBJECTIVE OF THIS PROPOSAL IS TO CARRY OUT INFLUENZA VIROLOGICAL, SEROLOGICAL, EPIDEMIOLOGICAL AND DISEASE SURVEILLANCE IN SPANISH SWINE POPULATION (INCLUDING WHITE AND FREERANGE IBERIAN PIGS AND WILD BOARS) AS PART OF THE CRIP´S INTERNATIONAL ANIMAL INFLUENZA SURVEILLANCE NETWORK. THE SPECIFIC AIMS ARE: 1. TO INCREASE THE KNOWLEDGE OF SWINE INFLUENZA VIRUSES CIRCULATING IN SPAIN: A. SUBTYPE IDENTIFICATION B. ANTIGENIC CHARACTERIZATION C. GENETIC CHARACTERIZATION D. PHENOTYPIC CHARACTERIZATION 2. TO INVESTIGATE THE INTERSPECIES TRANSMISSION OF INFLUENZA VIRUSES AT THE INTERFACE WILD BIRDS/SWINE (WHITE AND IBERIAN PIGS, WILD BOARS) AND THE EVOLUTION OF VIRUSES. WE SHALL PROVIDE: A. GEOGRAPHIC AND ECOLOGICAL INFORMATION (HABITAT, PRESENCE OF WATERFOWL OR OTHER WILD OR DOMESTIC MAMMAL OR BIRD SPECIES OR HUMANS) OF LOCATIONS IN WHICH SAMPLES WILL BE COLLECTED B. SPECIES INFORMATION: NAME, AGE, DATE, SEX, HEALTH STATUS C. SPECIMEN INFORMATION: ENVIRONMENT, SWAB, TISSUE, SERUM. 3. WE SHALL COLLECT, PROCESS AND ANALYZE SAMPLES ACCORDING STANDARDIZED METHODS VALIDATED BY CRIP. 4. DELIVERABLES: A. REPOSITORY OF INFLUENZA VIRUSES AND SERA B. METADATA AND GENOME SEQUENCE INFORMATION ON COLLECTED INFLUENZA VIRUSES C. SPECIFICITY INFORMATION ON COLLECTED SERA D. PROGRESS AND FINAL REPORTS E. PUBLICATIONS”

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.